ADMA Biologics Q3 revenue $41.1M (+99% YoY); raises FY2022 guidance to $145M

ADMA BIOLOGICS, INC.

2022-Q3 EPS reported -$0.27 revenue$104,098,237

Q3 revenue $41.1M (+99% YoY from $20.7M); gross profit $9.7M vs $0.4M; net loss $14.9M ($0.08 loss/share) narrowing from $17.7M.
FY2022 revenue guidance raised to ~$145M from prior $130M; reiterates profitability target no later than Q1 2024.
ASCENIV record pull-through; ongoing strategic review with Morgan Stanley; BioCenters on track for 10 FDA-licensed centers by 2023.
Long-term targets: revenue $250M+ in 2024, $300M+ thereafter; gross margins 40-50%, net income margins 20-30%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

ADMA BIOLOGICS, INC. reported the three months ended September 30, 2022 results: revenue $41.1 million. Guidance raised.

Period: the three months ended September 30, 2022
Revenue: $41.1 million
Guidance: raised
Result: reported results

Exact text from the filing

2 brhc10043955_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update 3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Increase Raising FY 2022 Total Revenue Guidance to $145 Million From $130 Million Previously

View on SEC.gov

Browse all earnings releases →

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-22-040700

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.